Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Interest Expenses (2016 - 2020)

Outlook Therapeutics (OTLK) has disclosed Interest Expenses for 6 consecutive years, with $443624.0 as the latest value for Q2 2020.

  • On a quarterly basis, Interest Expenses fell 58.99% to $443624.0 in Q2 2020 year-over-year; TTM through Jun 2025 was $443624.0, a N/A change, with the full-year FY2024 number at $3.2 million, up 24.72% from a year prior.
  • Interest Expenses was $443624.0 for Q2 2020 at Outlook Therapeutics, down from $696151.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.5 million in Q3 2017 to a low of $210183.0 in Q3 2019.
  • A 5-year average of $915984.1 and a median of $819376.5 in 2017 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: skyrocketed 482.94% in 2017, then plummeted 80.98% in 2019.
  • Outlook Therapeutics' Interest Expenses stood at $489145.0 in 2016, then soared by 46.76% to $717883.0 in 2017, then skyrocketed by 56.13% to $1.1 million in 2018, then crashed by 46.68% to $597665.0 in 2019, then fell by 25.77% to $443624.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Interest Expenses are $443624.0 (Q2 2020), $696151.0 (Q1 2020), and $597665.0 (Q4 2019).